Starting in 2021, the Immunocine Cancer Center is based in Cancun, Mexico. Immunocine was founded for the sole purpose of bringing revolutionary immunotherapy to cancer patients unable to participate in ongoing FDA Clinical Trials.
Leveraging a novel approach to Dendritic Cell Treatments, Immunocine’s protocol was first discovered in 2006 within the world-renowned Houston Medical Center.
With over 100 patients and 15 different types of cancer treated, this unique therapy provides a scientifically vetted alternative for cancer patients either out of options or looking for the cutting edge of immunotherapy.
The treatment is spread over six weeks, which includes a biopsy and three individual treatments.
The cost of the treatment is $85,000.
The price includes:
The Immunocine Team includes two dedicated concierges to assist with travel to and from Cancun, as well as any other needs such as hotel recommendations and booking.
Patients will additionally receive pre-and post-treatment bloodwork, biopsy analysis, and CT Scans. Additionally, Immunocine employs a thorough post-treatment check-up process to continue coordination with the patient’s physicians for updated analysis.
Dr. Alberto Ortiz, Chief Medical Officer
Dr. Alberto Ortiz received his medical degree from Benemerita Universidad Autónoma de Puebla. His training background includes extensive rotations in Pediatrics and Internal Medicine.
Currently certified in Neonatal Reanimation and Advanced Cardiovascular Life Support by the American Heart Association, Dr. Ortiz has spent the last six years working in Regenerative Medicine and Immunotherapy. In addition, he is now a current fellow at the Medical Academy of Pediatric Special needs (MAPS) and the American Academy of Antiaging Medicine (A4M).
Serving as the Chief Medical Officer for the Immunocine Cancer Center, Dr. Ortiz leads all patient medical evaluations, treatment, and post-treatment follow-ups. Supported by specialists in oncology, hematology, and radiology, Dr. Ortiz ensures that every patient receives the highest medical treatment and attention.
Dr. Ortiz has had the privilege of providing the most advanced and personalized immunotherapy treatment to patients from all over the world. Guided by a resolute medical discipline and ethics, Dr. Ortiz has given his patients hope in their fight against cancer.
Dr. Matt Halpert, President
Dr. Matthew Halpert earned his doctorate at the University of Alabama-Birmingham (UAB) and then spent 10 years at Baylor College of Medicine in Houston as a Cancer Immunologist. During his research, Dr. Halpert published research in some of the most prestigious peer-reviewed journals, has been cited over 300 hundred times, and became one of the leading experts in regard to cutting-edge cancer immunotherapy.
Additionally, he has founded a cancer-focused charity called Cancer Cures 4 Kids and Diakonos Research, which is currently studying its revolutionary Dendritic Cell Treatment in multiple FDA clinical trials.
In 2021, Dr. Halpert left Baylor College of Medicine to found the Immunocine Cancer Center, which leverages the Dendritic Cell Treatment currently being studied by the FDA. His singular goal in this effort is to provide this revolutionary cancer immunotherapy to patients that cannot wait for treatment.
The nature of the protocol requires an isolated sample of the protocol and therefore, the Immunocine Cancer Center only treats patients with solid tumors. As this patented protocol instructs the immune system to attack any cell genetically similar to the cells collected, it is not limited to specific cancer types.
Though each patient and each patient’s immune response is unique, there has not yet been identified cancer that this approach is incapable of immuno-educating, and complete responses in a variety of late-stage cancer patients have been observed.